Selenium sulfide is under clinical development by Azura Ophthalmics and currently in Phase II for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase II drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Selenium sulfide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Selenium sulfide overview
Selenium sulfide (AZRMD-001) is under development for the treatment of dry eye disease and contact lens intolerance or discomfort which is caused by meibomian gland dysfunction. It is administered through ophthalmic route in the form of emulsion ointment.
Azura Ophthalmics overview
Azura Ophthalmics is a biotechnology company that develops ophthalmic keratolytic for the treatment of ocular surface diseases. It is investigating AZR-MD-001 and AZR-MD-002 programs against meibomian gland dysfunction; AZR-MD-001 to treat evaporative dry eye and contact lens discomfort; and AZR-BL-007 and AZR-BL-008 compounds targeting blepharitis. The company is also evaluating AZR-AD-004 and AZR-AD-005 for aqueous deficient dry eye; and AZR-AE-006 for the treatment of acute exacerbation of dry eye. It was funded Ganot, MRCF, TPG Biotech, and OrbiMed. Azura Ophthalmics is headquartered Tel Aviv, Israel.
For a complete picture of Selenium sulfide’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
